Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
209 hedge funds and large institutions have $2.41B invested in Portola Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 74 increasing their positions, 48 reducing their positions, and 23 closing their positions.
126% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 23
76% more capital invested
Capital invested by funds: $1.37B → $2.41B (+$1.04B)
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
54% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 48
15% more funds holding
Funds holding: 181 → 209 (+28)
67% less call options, than puts
Call options by funds: $8.72M | Put options by funds: $26M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$44.6M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
+$35.3M |
| 3 |
DM
Deerfield Management
New York
|
+$27.1M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$16.6M |
| 5 |
JP Morgan Chase
New York
|
+$14.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
-$71.8M |
| 2 |
Morgan Stanley
New York
|
-$63M |
| 3 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
-$24.1M |
| 4 |
Citigroup
New York
|
-$15.9M |
| 5 |
AAMU
Amundi Asset Management US
Boston,
Massachusetts
|
-$14.1M |
PTLA Hedge Fund Activity: Q1 2019 in Review
209 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q1 2019, worth a combined $2.41B — up 76% from $1.37B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new PTLA positions and 23 closed out — a net gain of 29 holders — while 74 added to existing stakes and 48 trimmed.
The largest buyer was Fiera Capital (Canada), opening a new position worth an estimated $44.6M. The largest seller was Cadian Capital Management, cutting an estimated $71.8M.
- 209 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q1 2019, up from 181 in Q4 2018.
- Funds reported $2.41B of Portola Pharmaceuticals, Inc. stock for Q1 2019, up 76% quarter-over-quarter.
- 52 funds opened new Portola Pharmaceuticals, Inc. positions in Q1 2019 and 23 closed out, a net change of +29 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q1 2019 was Fiera Capital (Canada), an estimated $44.6M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q1 2019 was Cadian Capital Management, an estimated $71.8M sold.
Based on aggregated 13F filings for Q1 2019.